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Introduction
The thiazolidinedione-containing drug, pioglitazone ( Fig. 1) is used in the treatment of type 2 diabetes mellitus (Chilcott et al., 2001) . Pioglitazone is a member of the thiazolidinedione class agents, glitazones, and increases insulin sensitivity in target tissues by way of interaction with the peroxisome proliferator-activated receptor gamma (PPARγ) (Sood et al., 2000) . Several metabolites of pioglitazone in animals DMD #31583 6 For pioglitazone, the reactive intermediates of pioglitazone and their presumed metabolic pathway, which is similar to that of troglitazone, were also reported (Baughman et al., 2005) . They have identified the oxidative thiazolidinedione ring-opened products of pioglitazone (M-X) in rat and human liver microsomes. In addition, they have identified its ring-opened glutathione conjugates of pioglitazone (M-A and M-B) in rat and human liver microsomes and suspensions of freshly isolated rat hepatocytes.
In this study, we performed a detailed characterization of the metabolites of pioglitazone by employing hepatocyte incubation, radioactivity detection high-performance liquid chromatography (radio-HPLC), and LC/MS/MS techniques in order to understand further the potential metabolic pathways of the drug.
DMD #31583
ArCH 2 CH), 3.75 (3H, d, J = 3.5 Hz, CO 2 CH 3 ), 4.12 (1H, t, J = 7.2 Hz, C 5 -H), 4.3-4.4 (3H, m, PyCH 2 CH 2 O, C 1 -H), 5.3-5.4 (3H, m, C 2 -H, C 3 -H, C 4 -H), 5.9-6.0 (1H, m, ArCH 2 CH), 6.85 (2H, dd, J = 4.9 and 8.6 Hz, Ar-H), 7.10 (2H, dd, J = 1.6 and 8.6 Hz, Ar-H), 7.18 (1H, d, J = 7.8 Hz, Py-H), 7.45 (1H, dd, J = 1.9 and 7.8 Hz, Py-H), 8.39 (1H, d, J = 1.9 Hz, Py-H).
3-((2R,3R,4S,5S,6S)-6-allyloxycarbonyl-3,4,5-trihydroxy-tetrahydropyran-2-yl)-5-{4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzyl}-thiazolidine-2,4-dione (3).
A solution of 2 (4.26 g, 6.33 mmol), allyl alcohol (80 ml), and 4 N hydrogen chloride-dioxane (80 ml) was stirred for 4 h at room temperature and left standing for 3 days at room temperature. The reaction mixture was evaporated to dryness under reduced pressure.
The residue was diluted with a 5:1 by volume mixture of methylene chloride and 2-propanol (150 ml), added to water (150 ml), and treated with 1 N NaOH solution until the aqueous layer was neutralized to pH 4. The organic layer was separated and the water layer was extracted with a 5:1 by volume mixture of methylene chloride and 2-propanol. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate, after which the solvent was removed by evaporation under reduced pressure. The residue was purified by column chromatography with silica gel (200 g, 70 × 300 mm) using a gradient elution method, where a mixture of methylene chloride and methanol (volume ratios ranging from 30:1 to 10:1, respectively) was used by increasing the percentage of methanol gradually, to give 3.10 
LC/MS and LC/MS/MS analyses.
The conditions described below were used for the LC/MS and LC/MS/MS analyses of pioglitazone metabolites formed during incubation with human, rat, and monkey hepatocytes. These analyses were performed using a Q-Tof mass increased linearly to 50% solvent B for 30 min, increased linearly to 90% solvent B for 5 min, and was then held at 90% solvent B for 5 min. The flow rate was set at 0.1 ml/min and the elution flow from HPLC was introduced into the Q-Tof mass spectrometer ionization source through an ESI interface.
The conditions described below were used for the LC/MS and LC/MS/MS analyses of the generated products of M7 in human liver S9. These analyses were performed using a Waters Q-Tof Premier mass spectrometter (Waters, Manchester, UK) with a Waters ACQUITY UPLC system (Waters, Milford, MA) consisting of a binary solvent manager, a sample manager, a photodiode array (PDA) detector, and a column heater. The LC/MS analysis was conducted using ESI in the positive ion mode. The capillary voltage and cone voltage were set at 3300 V and 40 V, respectively. The source temperature and desolvation gas temperature were 120°C
and 300°C, respectively. The mass range from m/z 50 to 1000 was acquired with an integration time of 0.5 sec. The LC/MS/MS analysis was performed using a collision energy of 25 eV and argon as the collision gas. Chromatographic separation was performed on a YMC-UltraHT Pro C18 column (2.0 × 50 mm, 2 μm); the column temperature was maintained at 40°C, and UV detection was carried out at 225 nm.
The mobile phase consisted of water containing 0.01% TFA (solvent A) and acetonitrile containing 0.01% TFA (solvent B). The gradient started at 10% solvent B and increased linearly to 20% solvent B for 9 min. The flow rate was set at 0.2 ml/min, and the elution flow from UPLC was introduced into the Q-Tof ionization source through an ESI interface.
This article has not been copyedited and formatted. The final version may differ from this version. Based on these results, M11 was proposed to be a thiazolidinedione ring-opened methylmercapto carboxylic acid (Fig. 9) .
Metabolism of M7 in human liver S9.
The metabolism of M7 was studied using human liver S9. Incubation of M7
with human liver S9 in the presence of SAM yielded a thiazolidinedione ring-opened N-glucuronide M2, a newly generated product in human liver S9 (S9P1), and a thiazolidinedione ring-opened methylmercapto carboxylic acid M11 (Fig. 10) .
Incubation of M7 with human liver S9 in the absence of SAM yielded M2 and S9P1
(data not shown). M2 and S9P1 also resulted from incubation of M7 without human liver S9 and with SAM alone (data not shown).
Structure analysis of S9P1.
The 
Discussion
In this study, we detected thirteen metabolites (M1-M13) in an in vitro metabolic system of pioglitazone with freshly isolated human, rat, and monkey hepatocytes, and their structures were elucidated by LC/MS/MS. Furthermore, metabolites M2, S9P1, and M11 were detected in an in vitro metabolic system with human liver S9 using M7
(authentic standard) as a substrate. Based on the structures of the elucidated metabolites, the in vitro metabolic pathways for pioglitazone are proposed, as shown in Novel metabolic pathways for pioglitazone, N-glucuronidation of the thiazolidinedione ring of pioglitazone to form M7 and hydrolysis of M7 to form M2, were observed in hepatocytes. As a result of the presence of these metabolites, the metabolic pathway via the thiazolidinedione ring N-glucuronide M7 and subsequent hydrolysis to the thiazolidinedione ring-opened N-glucuronide M2 is proposed. This thiazolidinedione ring opening pathway is distinct from the known oxidative thiazolidinedione ring opening pathway for troglitazone (Kassahun et al., 2001 ) and pioglitazone (Baughman et al., 2005) . Baughman group has investigated the metabolites related to reactive metabolite formation using non-labeled pioglitazone (10 μM) in freshly isolated human hepatocytes by the detection method of a generic neutral loss method of 129 amu. However, they have not found N-glucuronide of pioglitazone. On the other hand, we have focused on the exhaustive investigation to find minor metabolites in freshly isolated hepatocytes using [ 14 C]pioglitazone (30 μM).
Moreover, in the human liver S9 study using M7, we inferred that M7 is metabolized to S9P1 via M2 and consequent S-methylation to M11 immediately in the This article has not been copyedited and formatted. The final version may differ from this version. (Uchiyama et al., 2010) . Thus, the metabolic pathways of ring opening via N-glucuronidation of the thiazolidinedione ring are assumed to be common metabolic reactions to the thiazolidinedione ring.
As examples of N-glucuronidation to analogs related to thiazolidinediones, N-glucuronides of MaxiPost (BMS-204352) (Zhang et al., 2005) , Bucolome (Mohri et al., 1985) , 5-ethyl-5-phenylhydantoin (Nirvanol) (Maguire et al., 1982) for Reddy et al., 2005) . In this study, we have identified M8, M1, and M3 as new metabolites of pioglitazone via the thiazolidinedione ring-opened mercapto amide. We estimate that these metabolites are sequentially generated by the oxidative thiazolidinedione ring opening and subsequent pathways, which agree well with the previous proposed metabolic activation scheme of pioglitazone (Baughman et al., 2005) .
Besides those described above, the known metabolic pathways for pioglitazone (Krieter et al., 1994; Kiyota et al., 1997; Maeshiba et al., 1997; Shen et al., 2003) were Some toxicological concerns have been expressed regarding the oxidative thiazolidinedione ring opening reaction of thiazolidinedione-containing drugs (Kassahun et al., 2001; Tettey et al., 2001; Smith, 2003; He et al., 2004; Baughman et al., 2005; Alvarez-Sanchez et al., 2006) . was incubated with freshly isolated human, rat, and monkey hepatocytes for 3 h at 37°
C. Radio-HPLC analysis was conducted as described in Materials and Methods. 
